Is Samsung C&T a Lagging Samsung Electronics Proxy? 51.7% Pass-Through, 0.83 Beta and the NAV Gap Trade
PharmaResearch Re-Rating Check: Can Rejuran Move From Medical Device Monopoly to U.S. Derma-Cosmetics Platform?
Pamicell (005690) Part 3 — 1Q26 Earnings Confirmation: Revenue ₩36.7bn, OP ₩13.1bn, OPM 35.7%. Above Consensus on All Lines